Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Combination therapies might work better for some vitiligo patients, but results vary.

This study reports that LL-37 treatment enhances cell proliferation, migration, and secretion of regenerative factors in adipose-derived stem cells, potentially promoting hair growth in vivo.

This study investigated the role of the glycoprotein Thy-1 in hypertrophic scar formation using a murine model, finding that Thy-1 knockdown reduced scar size and encouraged functional regeneration by influencing the p38MAPK signaling pathway under high-tension conditions.

This study identified Th22 cells as key effectors in hair regeneration driven by thymosin beta 15, suggesting they could be potential targets for hair regrowth therapies.

This source reports that for treating keloids and hypertrophic scars, combination pharmacotherapy targeting multiple sites is generally more effective than using a single drug, though outcomes of individual therapies vary and the development of satisfying treatments is ongoing.

This study identified at least four distinct fibroblast populations in adult human skin, each with unique functional properties, suggesting potential therapeutic applications for wound healing and fibrosis-related diseases.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This review explores the emerging roles of NK cells in various diseases, including allergies and skin conditions, and reports no new clinical results while indicating NK cell involvement in immune processes.

This study concluded that cytokines and growth factors significantly regulate hair growth in vitro, with some completely inhibiting growth, such as EGF and TNFα.

This study found that 17β-estradiol inhibited RANTES production in human keratinocytes by suppressing nuclear factor κB activity, suggesting a potential mechanism for 17β-estradiol's modulation of psoriasis-related inflammation.

This study highlights the need for further research on dysregulated immune and fibrotic pathways in morphea to better understand its pathogenesis and develop new biomarkers and therapies.

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.

This study established a new mouse model for TCE-induced skin sensitization and reported that proinflammatory cytokines TNF-α, IFN-γ, and IL-2 significantly contribute to this sensitization process.

In this study, IFN-γ-stimulated iPSC-derived mesenchymal stem cell extracellular vesicles improved atopic dermatitis in mice by reducing Th2 cytokine activity, suppressing inflammation, and restoring skin barrier function, as evidenced by decreased itching and inflammatory markers.

This study found that pentoxifylline plus topical corticosteroids had the highest treatment success rate for alopecia areata compared to no treatment, but the best overall treatment remains uncertain due to varying data.

This study investigated immune dysregulation in individuals with Down syndrome and found that treatment with the JAK inhibitor tofacitinib improved skin conditions like alopecia areata and reduced autoimmune markers without severe side effects. Additional research is necessary to understand its broader impacts.

This study indicates that innate lymphoid cells-type 1 may provoke alopecia areata by disrupting hair follicle immune privilege and inducing characteristic lesions, challenging the view that alopecia areata is purely an autoantigen-dependent, T cell-driven condition.

This study suggests that SOCS3 treatment may effectively inhibit alopecia areata by suppressing CD8+ T cell activity and IFN-γ production.

This study found that human hematopoietic mesenchymal stem cells increased the viability and migration of human outer root sheath cells in an in vitro alopecia areata model, involving Wnt/β-catenin and JAK/STAT pathways.

This review discusses mechanisms of wound healing impairment in leptin-deficient murine models used for diabetic research, and reports no new clinical results; the authors emphasize the need for further study.

This review discusses the complex role of immune disturbances and the JAK-STAT pathway in alopecia areata, noting the success of JAK inhibitors in treatment, while highlighting ongoing debates and challenges in targeting other pathways like IL-17 and TNF-α.

This study observed that individuals with Down syndrome exhibit early immune dysregulation, including multi-organ autoimmunity and hypercytokinemia, and found that the JAK inhibitor tofacitinib showed a good safety profile and reduced skin pathology in a Phase II trial.

This study identified dual epithelial and mesenchymal traits in dermal sheath cells during wound repair, suggesting they could be targeted to enhance healing.

This study found that forming inclusion complexes of DPCP with HPβCD using the 3D ground mixture method enhances its anti-inflammatory activity at lower doses compared to complexes with β-CD.

This study found that patients with alopecia areata and their healthy family members had elevated levels of Th1- and Th17-related cytokines, suggesting a genetic link in cytokine dysregulation.

This study found that PBMCsec has anti-fibrotic effects on mouse and human skin scars by regulating pro-fibrotic gene expression and inhibiting myofibroblast differentiation and elastic fiber breakdown.

This study reports that topical fish oil treatment in GsdmA3 Dfl/+ mice increased cellular proliferation and macrophages but did not affect COX-2 expression related to psoriasis-like skin changes.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

This study found that ILC1-like cells can induce alopecia areata symptoms in both ex vivo human hair follicles and in vivo mouse models, challenging the view that alopecia areata is solely CD8+ T cell-driven.

This report describes a case of alopecia universalis successfully treated with tofacitinib, though it was associated with increased peripheral blood cytokine levels.